Calithera Biosciences Inc. (CALA) Sees Unusually-High Trading Volume
Calithera Biosciences Inc. (NASDAQ:CALA) saw unusually-strong trading volume on Friday . Approximately 191,672 shares changed hands during trading, a decline of 8% from the previous session’s volume of 207,369 shares.The stock last traded at $3.65 and had previously closed at $3.61.
Several research analysts recently weighed in on CALA shares. Zacks Investment Research upgraded Calithera Biosciences from a “hold” rating to a “buy” rating and set a $6.50 price target for the company in a research report on Tuesday, March 22nd. Wells Fargo & Co. reissued a “buy” rating on shares of Calithera Biosciences in a report on Thursday, May 12th. Finally, JMP Securities reissued a “buy” rating on shares of Calithera Biosciences in a report on Wednesday, June 8th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Calithera Biosciences currently has a consensus rating of “Buy” and an average target price of $10.48.
The stock has a 50-day moving average price of $4.56 and a 200 day moving average price of $5.41. The firm’s market capitalization is $68.81 million.
Calithera Biosciences (NASDAQ:CALA) last posted its quarterly earnings data on Tuesday, May 10th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.47) by $0.05. On average, analysts anticipate that Calithera Biosciences Inc. will post ($2.15) earnings per share for the current year.
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.